June 2022
1. WOLOSHIN S, Kesselheim AS
   What to Know About the Alzheimer Drug Aducanumab (Aduhelm).
   JAMA Intern Med. 2022 Jun 6. pii: 2792897. doi: 10.1001/jamainternmed.2022.1039.
   

   >> Share

   
   March 2022
2. PALAN LOPEZ R, Hendricksen M, McCarthy EP, Mazor KM, et al
   Association of Nursing Home Organizational Culture and Staff Perspectives With Variability in Advanced Dementia Care: The ADVANCE Study.
   JAMA Intern Med. 2022;182:313-323.
   

   >> Share

   
   February 2022
3. LEE CS, Gibbons LE, Lee AY, Yanagihara RT, et al
   Association Between Cataract Extraction and Development of Dementia.
   JAMA Intern Med. 2022;182:134-141.
   

   >> Share

   
   December 2021
4. LARGENT EA, Peterson A, Lynch HF
   FDA Drug Approval and the Ethics of Desperation.
   JAMA Intern Med. 2021;181:1555-1556.
   

   >> Share

   
   October 2021
5. CROSSON FJ, Covinsky K, Redberg RF
   Medicare and the Shocking US Food and Drug Administration Approval of Aducanumab: Crisis or Opportunity?
   JAMA Intern Med. 2021;181:1278-1280.
   

   >> Share

   
   July 2021
6. STEINBROOK R
   The Accelerated Approval of Aducanumab for Treatment of Patients With Alzheimer Disease.
   JAMA Intern Med. 2021 Jul 13. pii: 2782122. doi: 10.1001/jamainternmed.2021.4622
   

   >> Share

   
   
7. DUNN B, Stein P, Cavazzoni P
   Approval of Aducanumab for Alzheimer Disease-the FDA's Perspective.
   JAMA Intern Med. 2021 Jul 13. pii: 2782119. doi: 10.1001/jamainternmed.2021.4607
   

   >> Share

   
   
8. MITCHELL SL, D'Agata EMC, Hanson LC, Loizeau AJ, et al
   The Trial to Reduce Antimicrobial Use in Nursing Home Residents With Alzheimer Disease and Other Dementias (TRAIN-AD): A Cluster Randomized Clinical Trial.
   JAMA Intern Med. 2021 Jul 12. pii: 2782003. doi: 10.1001/jamainternmed.2021.3098
   

   >> Share

   
   November 2020
9. NICHOLAS LH, Langa KM, Bynum JPW, Hsu JW, et al
   Financial Presentation of Alzheimer Disease and Related Dementias.
   JAMA Intern Med. 2020 Nov 30. pii: 2773241. doi: 10.1001/jamainternmed.2020.6432
   

   >> Share

   
   December 2019
10. BURKE JF, Langa KM
    Biomarker-Informed Treatment Decisions in Cognitively Impaired Patients Do Not Apply to Preclinical Alzheimer Disease-Reply.
    JAMA Intern Med. 2019;179:1737.
    

    >> Share

    
    
11. RABINOVICI GD, Carrillo MC
    Biomarker-Informed Treatment Decisions in Cognitively Impaired Patients Do Not Apply to Preclinical Alzheimer Disease.
    JAMA Intern Med. 2019;179:1736-1737.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share